Abstract
Based on preclinical studies and early clinical observations, an association between vitamin D status and breast cancer incidence and outcome has been proposed. Against this background, information on vitamin D and breast cancer was reviewed with focused attention on emerging clinical studies in this area. Prospective cohort studies do not associate 25-hydroxyvitamin D levels with breast cancer incidence. While case-control studies of this question are positive, they may be confounded by reverse causality as 25- hydroxyvitamin D levels are influenced by breast cancer presence and stage. Studies of 25-hydroxyvitamin D and subsequent breast cancer recurrence provide mixed results but strongest associations were seen in analyses uncontrolled for prognostic variables, cancer therapy, BMI and physical activity. The one full-scale randomized, placebo-controlled trial evaluating calcium (1000 mg elemental calcium per day) and vitamin D supplementation (400 IU D3 per day) with 36,282 participants failed to demonstrate a supplement effect on lowering breast cancer incidence. Breast cancer patients not uncommonly have vitamin D deficiency but limited control populations in available reports preclude precise prevalence estimates. As breast cancer patients are at risk for bone loss and musculoskeletal complaints from cancer or associated therapies, monitoring 25-hydroxyvitamin D levels and vitamin D3 supplementation in moderate dose (1,000- 1,500 IU D3 per day) can be recommended with expectation of mainly bone benefit. In women with breast cancer, future vitamin D supplementation studies need to be appropriately designed and powered to provide definitive assessments. However, a full-scale randomized trial evaluating the influence of vitamin D supplementation on breast cancer recurrence is likely not feasible.
Keywords: 25-hydroxyvitamin D, Breast cancer, Breast cancer incidence, Breast cancer prevention, Calcium, Case control studies, Cohort studies, Joint symptoms, Meta-analysis, Randomized clinical trials, Total mortality, Vitamin D
Anti-Cancer Agents in Medicinal Chemistry
Title:Vitamin D and Breast Cancer Incidence and Outcome
Volume: 13 Issue: 1
Author(s): Rowan T. Chlebowski
Affiliation:
Keywords: 25-hydroxyvitamin D, Breast cancer, Breast cancer incidence, Breast cancer prevention, Calcium, Case control studies, Cohort studies, Joint symptoms, Meta-analysis, Randomized clinical trials, Total mortality, Vitamin D
Abstract: Based on preclinical studies and early clinical observations, an association between vitamin D status and breast cancer incidence and outcome has been proposed. Against this background, information on vitamin D and breast cancer was reviewed with focused attention on emerging clinical studies in this area. Prospective cohort studies do not associate 25-hydroxyvitamin D levels with breast cancer incidence. While case-control studies of this question are positive, they may be confounded by reverse causality as 25- hydroxyvitamin D levels are influenced by breast cancer presence and stage. Studies of 25-hydroxyvitamin D and subsequent breast cancer recurrence provide mixed results but strongest associations were seen in analyses uncontrolled for prognostic variables, cancer therapy, BMI and physical activity. The one full-scale randomized, placebo-controlled trial evaluating calcium (1000 mg elemental calcium per day) and vitamin D supplementation (400 IU D3 per day) with 36,282 participants failed to demonstrate a supplement effect on lowering breast cancer incidence. Breast cancer patients not uncommonly have vitamin D deficiency but limited control populations in available reports preclude precise prevalence estimates. As breast cancer patients are at risk for bone loss and musculoskeletal complaints from cancer or associated therapies, monitoring 25-hydroxyvitamin D levels and vitamin D3 supplementation in moderate dose (1,000- 1,500 IU D3 per day) can be recommended with expectation of mainly bone benefit. In women with breast cancer, future vitamin D supplementation studies need to be appropriately designed and powered to provide definitive assessments. However, a full-scale randomized trial evaluating the influence of vitamin D supplementation on breast cancer recurrence is likely not feasible.
Export Options
About this article
Cite this article as:
T. Chlebowski Rowan, Vitamin D and Breast Cancer Incidence and Outcome, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (1) . https://dx.doi.org/10.2174/1871520611307010098
DOI https://dx.doi.org/10.2174/1871520611307010098 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Epigenetic Evaluation of N-(2-hydroxyphenyl)-2-Propylpentanamide, a Valproic Acid Aryl Derivative with Activity Against HeLa Cells
Current Molecular Pharmacology Combined Anticancer Therapies: An Overview of the Latest Applications
Anti-Cancer Agents in Medicinal Chemistry Mesenchymal Stem Cell-Based Therapy for the Treatment of Type 1 Diabetes Mellitus
Current Stem Cell Research & Therapy Recent Developments in PET Instrumentation
Current Pharmaceutical Biotechnology Circulating Biomarkers for Tumor Angiogenesis: Where Are We?
Current Medicinal Chemistry Identification and Characterization of SNP Mutation in Genes Related to Non-small Cell Lung Cancer
Current Signal Transduction Therapy A Conceptual Model of Psychoneurological Symptom Cluster Variation in Women with Breast Cancer: Bringing Nursing Research to Personalized Medicine
Current Pharmacogenomics and Personalized Medicine FMRI of the Emotions: Towards an Improved Understanding of Amygdala Function
Current Medical Imaging Patent Annotations
Recent Patents on Anti-Cancer Drug Discovery CBP-dependent Wnt/β-catenin signaling is crucial in regulation of MDR1 transcription
Current Cancer Drug Targets Immunotherapy for Prostate Cancer
Current Pharmaceutical Design Meet Our Associate Editorial Board Member
Mini-Reviews in Medicinal Chemistry Will Antiangiogenic Agents be a Future for Mesothelioma Therapy?
Current Medicinal Chemistry Synthetic Strategies Towards O6-Substituted Guanine Derivatives and their Application in Medicine
Current Organic Synthesis Immune System Induction of Nerve Growth Factor in an Animal Model of Multiple Sclerosis: Implications in Re-Myelination and Myelin RepairATION AND MYELIN REPAIR
CNS & Neurological Disorders - Drug Targets The Endocannabinoid System in Parkinsons Disease
Current Pharmaceutical Design Synthesis and Antiproliferative Activity of Coumarin-Estrogen Conjugates against Breast Cancer Cell Lines
Letters in Drug Design & Discovery Targeting Pain-evoking Transient Receptor Potential Channels for the Treatment of Pain
Current Neuropharmacology Design, Synthesis, Cytotoxic Activity and Apoptosis-inducing Action of Novel Cinnoline Derivatives as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Extracellular Vesicles as Novel Delivery Tools for Cancer Treatment
Current Cancer Drug Targets